Clinical trial · Interventional
Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics
Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics: Efficacy Study in Adults and Children. Randomized Prospective Study With Direct Individual Benefit
NCT00181012CI-TRIAL-00000876unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine prospectively the lidocaine efficacy in 2 types of patient populations with cancer (group A: children from 6 to 14 years old and group B: adults from 15 to 70 years old)
- timeFrame
- continuous intravenous perfusion for 6 days
Secondary outcomes (1)
- measure
- To confirm the tolerance of the lidocaine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy * Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults) * Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis * Pain resistant to morphinic treatment Exclusion Criteria: * Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months * Neurological: non-controlled epilepsy, encephalopathy, or dementia * Severe hepatic insufficiency * Severe renal insufficiency * Respiratory insufficiency * Patients having surgery or in postoperative period * Known deficit in G6PD, alanine exposure, or sulphamide treatment * Porphyria * Weight \> 80 kg
References
Publications (0)
Data not yet available
No reference posted for this study.